Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) had its price target boosted by Ladenburg Thalmann Financial Services from $27.00 to $30.00 in a report released on Thursday, September 7th. Ladenburg Thalmann Financial Services’ price objective would suggest a potential upside of 179.07% from the stock’s previous close.

Other equities analysts have also recently issued research reports about the company. Zacks Investment Research upgraded Avadel Pharmaceuticals PLC. from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Monday, July 17th. Roth Capital set a $15.00 price objective on Avadel Pharmaceuticals PLC. and gave the stock a “buy” rating in a research report on Wednesday, August 9th.

Avadel Pharmaceuticals PLC. (NASDAQ AVDL) traded up 4.140% on Thursday, reaching $11.195. The company had a trading volume of 122,037 shares. The company’s 50 day moving average price is $9.30 and its 200-day moving average price is $9.78. The company has a market capitalization of $448.74 million, a price-to-earnings ratio of 12.168 and a beta of 1.47. Avadel Pharmaceuticals PLC. has a 12 month low of $8.14 and a 12 month high of $13.25.

Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $0.19 EPS for the quarter, beating the Zacks’ consensus estimate of $0.05 by $0.14. The firm had revenue of $46.30 million for the quarter, compared to analyst estimates of $45.17 million. Avadel Pharmaceuticals PLC. had a return on equity of 29.84% and a net margin of 21.13%. The firm’s revenue was up 19.0% compared to the same quarter last year. On average, equities analysts predict that Avadel Pharmaceuticals PLC. will post $1.16 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/08/flamel-technologies-s-a-avdl-given-new-30-00-price-target-at-ladenburg-thalmann-financial-services.html.

In other news, Director Peter J. Thornton purchased 5,155 shares of the firm’s stock in a transaction dated Thursday, September 21st. The stock was bought at an average price of $9.74 per share, with a total value of $50,209.70. Following the acquisition, the director now directly owns 5,155 shares of the company’s stock, valued at $50,209.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael S. Anderson purchased 4,000 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The stock was purchased at an average cost of $9.80 per share, with a total value of $39,200.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 46,855 shares of company stock valued at $445,058 in the last ninety days. Company insiders own 5.07% of the company’s stock.

A number of institutional investors have recently modified their holdings of AVDL. State Street Corp lifted its holdings in Avadel Pharmaceuticals PLC. by 1.7% during the second quarter. State Street Corp now owns 31,782 shares of the company’s stock worth $351,000 after acquiring an additional 523 shares in the last quarter. Stifel Financial Corp increased its holdings in shares of Avadel Pharmaceuticals PLC. by 4.3% in the second quarter. Stifel Financial Corp now owns 60,500 shares of the company’s stock worth $667,000 after acquiring an additional 2,500 shares in the last quarter. Sei Investments Co. raised its position in shares of Avadel Pharmaceuticals PLC. by 29.5% during the second quarter. Sei Investments Co. now owns 12,726 shares of the company’s stock worth $140,000 after purchasing an additional 2,900 shares during the period. Trexquant Investment LP raised its position in shares of Avadel Pharmaceuticals PLC. by 30.7% during the second quarter. Trexquant Investment LP now owns 30,500 shares of the company’s stock worth $336,000 after purchasing an additional 7,169 shares during the period. Finally, Columbus Circle Investors raised its position in shares of Avadel Pharmaceuticals PLC. by 16.7% during the second quarter. Columbus Circle Investors now owns 51,137 shares of the company’s stock worth $564,000 after purchasing an additional 7,315 shares during the period. 69.09% of the stock is currently owned by institutional investors and hedge funds.

Avadel Pharmaceuticals PLC. Company Profile

Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results.

Receive News & Stock Ratings for Avadel Pharmaceuticals PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals PLC. and related stocks with our FREE daily email newsletter.